Nigeria: Counterfeit Cancer Drugs - NAFDAC Raises Alarm Over Fake Avastin, Tecentriq

Nigeria's pharmaceutical sector is experiencing a critical convergence of crises that threatens both patient outcomes and investor confidence in Africa's largest healthcare market. The National Agency for Food and Drug Administration and Control (NAFDAC) has issued urgent warnings regarding the circulation of counterfeit oncology medications, specifically Avastin and Tecentriq, while simultaneously, the healthcare system faces severe funding shortfalls that are undermining immunisation programmes and broader service delivery infrastructure. These parallel challenges reveal a troubling reality: Nigeria's healthcare market, despite its 220 million-person population and significant middle-class expansion, remains vulnerable to systemic failures that jeopardise both public health outcomes and the viability of legitimate pharmaceutical investments. **The Counterfeit Medicine Epidemic** The circulation of fake Avastin (bevacizumab) and Tecentriq (atezolizumab)—both essential monoclonal antibody therapies for advanced cancers—represents more than a quality control problem. These are high-value medications, with Avastin costing approximately $2,500-$5,000 per treatment cycle. The prevalence of counterfeits suggests an established black market network exploiting cancer patients and their families, who often face desperate circumstances and limited access to authenticated pharmaceutical supply chains. For European pharmaceutical companies and distributors, this signals a market where brand protection requires substantial investment in authentication infrastructure, supply chain monitoring, and regulatory partnership. The reputational risk